Clinical Trial

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-24; most recent amendment 2025-07-14.
Status change: Not Yet Recruiting → Recruiting 2023-10-16
Trial Details
NCT Number NCT06019923
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Conditions Ovarian Cancer
Enrollment 100 participants
Start Date 2023-10-26
Primary Completion 2026-09-10 (estimated)
Study Completion 2027-09-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-17